VVZ 368

Drug Profile

VVZ 368

Alternative Names: VVZ-368

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vivozon
  • Class Analgesics
  • Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 28 Apr 2017 Early research in Pain in USA (PO) (Vivozon pipeline, April 2017)
  • 28 Apr 2017 Vivozon has patent protection for benzamide derivatives for the treatment of pain in Korea, USA and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top